Clinical Trial Update: Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Disitamab Vedotin with RC148 vs nab-paclitaxel +/- toripalimab in HR-/HER2-low breast cancer; study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Nab-paclitaxel (paclitaxel protein-bound)
• RC148 (RC148)
• Toripalimab (Toripalimab)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING